Skip to main content
Medprin Regenerative Medical Technologies Co.,Ltd. logo

Medprin Regenerative Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 301033 ISIN · CNE100004NB8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 716 across all filing types
Latest filing 2026-05-25 M&A Activity
Country CN China
Listing Shenzhen Stock Exchange 301033

About Medprin Regenerative Medical Technologies Co.,Ltd.

https://www.medprin.com

Medprin Regenerative Medical Technologies Co., Ltd. specializes in the development and manufacturing of high-performance implantable medical devices using advanced regenerative medicine and biomimetic material technologies. The company focuses on providing innovative solutions for neurosurgery, orthopedics, and cranio-maxillofacial surgery. Its core product portfolio includes the ReDura series of biomimetic synthetic dural substitutes, PEEK-based cranial and maxillofacial repair systems, and various absorbable surgical meshes. By leveraging proprietary 3D bioprinting and precision manufacturing platforms, Medprin creates implants designed to facilitate tissue regeneration and restore physiological functions. The company’s products are characterized by high biocompatibility and mechanical properties that closely mimic natural human tissues, serving a global clinical market with regulatory clearances across multiple international jurisdictions.

Recent filings

Filing Released Lang Actions
广州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）
M&A Activity Classification · 85% confidence The document is a detailed “发行股份及支付现金购买资产并募集配套资金暨关联交易报告书” – a prospectus‐style major asset reorganization report describing issuance of shares, cash payment to acquire assets and related fundraising. This is a large-scale M&A/asset restructuring filing rather than a simple announcement (RPA), governance change, or financial report. It falls under merger and acquisition activity disclosures. Therefore, the appropriate classification is M&A Activity (TAR).
2026-05-25 Chinese
关于本次交易所涉评估报告加期的公告
M&A Activity Classification · 85% confidence The document is an official announcement by Guangzhou Medprin regarding the extension (加期) of an asset valuation report tied to its planned issuance of shares and cash acquisition of a target company’s equity. It is not the valuation report itself, but an update in connection with an ongoing M&A transaction. This falls under 'M&A Activity' (Code: TAR).
2026-05-25 Chinese
第三届董事会第二十一次会议决议公告
Share Issue/Capital Change Classification · 86% confidence The document is a board resolution announcement (“董事会决议公告”) from Guangzhou Medprin, detailing the board’s approval of issuing shares and paying cash to acquire assets and to raise supporting funds. This constitutes an announcement of a new share issue and capital structure change, matching the definition of Share Issue/Capital Change (SHA).
2026-05-25 Chinese
关于发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）修订说明的公告
M&A Activity Classification · 75% confidence The document is a public announcement detailing revisions (“修订说明的公告”) to the draft related‐party transaction report (“关联交易报告书（草案）”) concerning the issuance of shares and cash to purchase assets and raise supporting capital. This is part of a major asset restructuring/acquisition transaction rather than an earnings release, board change, or certificate. It is not merely a report publication notice but the substantive amendment announcement for an M&A transaction filing. Therefore, it falls under the M&A Activity category (Code: TAR).
2026-05-25 Chinese
第三届董事会独立董事专门会议第十次会议审核意见
M&A Activity Classification · 55% confidence The document is the independent directors’ review opinions for a proposed share issuance and cash purchase of 100% equity in a target company, including fundraising, under China’s major asset reorganization rules. This is part of a transaction to acquire another business via share issuance/cash and is akin to M&A activity disclosures rather than a simple board change or dividend notice. Therefore it fits best under M&A Activity (TAR).
2026-05-25 Chinese
华泰联合证券有限责任公司关于广州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易之独立财务顾问报告（修订稿）
M&A Activity Classification · 85% confidence The document is a comprehensive Independent Financial Advisor Report (‘独立财务顾问报告’) prepared for a major asset restructuring involving issuance of shares, cash payment to acquire assets, and complementary fund raising by Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. This type of fairness opinion and detailed advisory report is part of a merger/acquisition or major asset reorganization process. It is neither a simple announcement nor a proxy solicitation letter alone, but rather the core advisory document required for shareholder approval in an M&A transaction. It therefore best fits the “M&A Activity” category (TAR).
2026-05-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.